↓ Skip to main content

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Overview of attention for article published in Cardiovascular Diabetology, January 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#40 of 1,321)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
2 news outlets
blogs
3 blogs
twitter
4 tweeters

Citations

dimensions_citation
185 Dimensions

Readers on

mendeley
287 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Published in
Cardiovascular Diabetology, January 2014
DOI 10.1186/1475-2840-13-102
Pubmed ID
Authors

Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman, Odd Johansen, Hans-Juergen Woerle, Uli C Broedl

Abstract

Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyond glycemia alone. The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes. The aim of the ongoing EMPA-REG OUTCOME™ trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on macro-/microvascular outcomes.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 287 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 2 <1%
Spain 1 <1%
Denmark 1 <1%
Germany 1 <1%
Unknown 282 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 43 15%
Student > Master 33 11%
Other 32 11%
Student > Bachelor 28 10%
Student > Ph. D. Student 26 9%
Other 55 19%
Unknown 70 24%
Readers by discipline Count As %
Medicine and Dentistry 139 48%
Pharmacology, Toxicology and Pharmaceutical Science 22 8%
Nursing and Health Professions 14 5%
Agricultural and Biological Sciences 11 4%
Biochemistry, Genetics and Molecular Biology 9 3%
Other 16 6%
Unknown 76 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2021.
All research outputs
#974,148
of 22,362,494 outputs
Outputs from Cardiovascular Diabetology
#40
of 1,321 outputs
Outputs of similar age
#12,298
of 309,311 outputs
Outputs of similar age from Cardiovascular Diabetology
#2
of 77 outputs
Altmetric has tracked 22,362,494 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,321 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,311 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.